Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT^® Autoinjector: A Prospective Observational Cohort Study.

ABSTRACT: Background: In patients with multiple sclerosis (MS), non-adherence to disease-modifying drug therapy is associated with an increased rate of MS relapses. Early identification of patients at risk of non-adherence would allow provision of timely and individualized support. The aim of the BETAPREDICT study was to investigate potential predictors of adherence in patients with MS in Germany treated with interferon β-1b (IFNβ-1b) using the BETACONNECT® autoinjector. Methods: BETAPREDICT was a national, multi-center, prospective, non-interventional, single-arm, 24-month cohort study of patients with relapsing-remitting MS or clinically isolated syndrome receiving IFNβ-1b via the BETACONNECT® autoinjector (ClinicalTrials.gov: NCT02486640). Injection data were captured by the autoinj

SUBMITTER: Kohler W 

PROVIDER: S-EPMC7943887 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature